Related Experiment Videos
Follicular lymphoma: the case for timely intervention
1University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. pmclaugh@mdanderson.org
Expert Review of Hematology
|November 19, 2010
Summary
Significant progress is being made in follicular lymphoma (FL) management, with cure now a realistic goal for select patients. Improved survival outcomes are largely attributed to the integration of anti-CD20 monoclonal antibodies into treatment regimens.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Follicular lymphoma (FL) management has seen limited progress for decades.
- Recent advancements offer new hope for patients with this indolent non-Hodgkin lymphoma.
Purpose of the Study:
- To highlight recent therapeutic advances in follicular lymphoma.
- To discuss the potential for achieving a cure in specific patient subsets.
- To emphasize the impact of novel treatment strategies on survival outcomes.
Main Methods:
- Review of current treatment strategies for follicular lymphoma.
- Analysis of survival data in relation to therapeutic interventions.
- Identification of patient groups with potential for curative treatment.
Main Results:
- Cure is becoming a realistic aim for certain follicular lymphoma patients, including those with early-stage disease (I-II), specific histologic subtypes (e.g., FL grade 3b), and some relapsed cases post-stem cell transplant.
- Survival outcomes have demonstrably improved.
- The inclusion of anti-CD20 monoclonal antibodies is a major contributor to enhanced survival.
Conclusions:
- Follicular lymphoma management is evolving, with a shift towards curative intent for some patients.
- Anti-CD20 monoclonal antibodies are critical components of modern FL treatment, significantly improving patient survival.
- Further research and personalized treatment approaches are essential for optimizing outcomes in follicular lymphoma.